Table 2.

Pooled week 48 efficacy outcomes for patients with known HBV and/or HCV coinfection status at baseline (N = 1335)

Efficacy parameters at week 48a	HIV patients with HBV/HCV coinfection		HIV patients without HBV/HCV coinfection
	25 mg of RPV once daily, N = 49	600 mg of EFV once daily, N = 63	25 mg of RPV once daily, N = 621	600 mg of EFV once daily, N = 602
Patients with viral load <50 copies/mL (ITT-TLOVR), % (95% CI)	73.5 (61–86)	79.4 (69–90)	85.0 (82–88)	82.6 (80–86)
Virological failures, n (%)	5 (10.2)	3 (4.8)	55 (8.9)	30 (5.0)
Discontinuation due to AE/death, n (%)	2 (4.1)	6 (9.5)	13 (2.1)	40 (6.6)
Discontinuation due to reason other than AEb, n (%)	6 (12.2)	4 (6.3)	25 (4.0)	35 (5.8)
Change in CD4 count (NC = Fc) from baseline (cells/mm3), mean (95% CI)d	+137 (100–175)	+192 (147–238)	+197 (186–209)	+173 (161–185)

RPV, rilpivirine; EFV, efavirenz.

^aPatients included in efficacy analysis were those with baseline HBV/HCV assessments.

^bLost to follow-up, non-compliance, withdrew consent, ineligible to continue, sponsor's decision.

^cNC = F, non-completer = failure: missing values after discontinuation imputed with change = 0; last observation carried forward otherwise.

^dN′ = 48 for rilpivirine for HBV- and/or HCV-coinfected patients.